S&P 500   3,769.96 (-2.07%)
DOW   30,433.44 (-1.63%)
QQQ   321.13 (-2.27%)
AAPL   142.55 (-0.43%)
MSFT   232.36 (+0.01%)
FB   273.28 (-3.11%)
GOOGL   1,821.35 (-4.54%)
AMZN   3,251.36 (-2.25%)
TSLA   875.40 (-0.87%)
NVDA   517.02 (-3.79%)
BABA   262.00 (-1.47%)
CGC   38.19 (+7.52%)
GE   10.76 (-4.69%)
MU   75.68 (-4.82%)
AMD   89.29 (-5.72%)
NIO   57.32 (-4.96%)
T   29.08 (-2.25%)
F   10.79 (-3.57%)
ACB   11.41 (+6.94%)
BA   192.94 (-4.51%)
DIS   163.06 (-3.83%)
NFLX   533.00 (-5.15%)
GILD   65.59 (-1.66%)
S&P 500   3,769.96 (-2.07%)
DOW   30,433.44 (-1.63%)
QQQ   321.13 (-2.27%)
AAPL   142.55 (-0.43%)
MSFT   232.36 (+0.01%)
FB   273.28 (-3.11%)
GOOGL   1,821.35 (-4.54%)
AMZN   3,251.36 (-2.25%)
TSLA   875.40 (-0.87%)
NVDA   517.02 (-3.79%)
BABA   262.00 (-1.47%)
CGC   38.19 (+7.52%)
GE   10.76 (-4.69%)
MU   75.68 (-4.82%)
AMD   89.29 (-5.72%)
NIO   57.32 (-4.96%)
T   29.08 (-2.25%)
F   10.79 (-3.57%)
ACB   11.41 (+6.94%)
BA   192.94 (-4.51%)
DIS   163.06 (-3.83%)
NFLX   533.00 (-5.15%)
GILD   65.59 (-1.66%)
S&P 500   3,769.96 (-2.07%)
DOW   30,433.44 (-1.63%)
QQQ   321.13 (-2.27%)
AAPL   142.55 (-0.43%)
MSFT   232.36 (+0.01%)
FB   273.28 (-3.11%)
GOOGL   1,821.35 (-4.54%)
AMZN   3,251.36 (-2.25%)
TSLA   875.40 (-0.87%)
NVDA   517.02 (-3.79%)
BABA   262.00 (-1.47%)
CGC   38.19 (+7.52%)
GE   10.76 (-4.69%)
MU   75.68 (-4.82%)
AMD   89.29 (-5.72%)
NIO   57.32 (-4.96%)
T   29.08 (-2.25%)
F   10.79 (-3.57%)
ACB   11.41 (+6.94%)
BA   192.94 (-4.51%)
DIS   163.06 (-3.83%)
NFLX   533.00 (-5.15%)
GILD   65.59 (-1.66%)
S&P 500   3,769.96 (-2.07%)
DOW   30,433.44 (-1.63%)
QQQ   321.13 (-2.27%)
AAPL   142.55 (-0.43%)
MSFT   232.36 (+0.01%)
FB   273.28 (-3.11%)
GOOGL   1,821.35 (-4.54%)
AMZN   3,251.36 (-2.25%)
TSLA   875.40 (-0.87%)
NVDA   517.02 (-3.79%)
BABA   262.00 (-1.47%)
CGC   38.19 (+7.52%)
GE   10.76 (-4.69%)
MU   75.68 (-4.82%)
AMD   89.29 (-5.72%)
NIO   57.32 (-4.96%)
T   29.08 (-2.25%)
F   10.79 (-3.57%)
ACB   11.41 (+6.94%)
BA   192.94 (-4.51%)
DIS   163.06 (-3.83%)
NFLX   533.00 (-5.15%)
GILD   65.59 (-1.66%)
Log in
NASDAQ:BCDA

BioCardia Stock Forecast, Price & News

$4.00
-0.09 (-2.20 %)
(As of 01/27/2021 02:34 PM ET)
Add
Compare
Today's Range
$3.70
Now: $4.00▼
$4.03
50-Day Range
$3.32
MA: $3.69▼
$4.39
52-Week Range
$1.91
Now: $4.00▼
$8.60
Volume7,163 shs
Average Volume453,037 shs
Market Capitalization$49.72 million
P/E RatioN/A
Dividend YieldN/A
Beta1.98
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.

MarketRank™

Overall MarketRank™

2.16 out of 5 stars

Medical Sector

28th out of 1,925 stocks

Biological Products, Except Diagnostic Industry

3rd out of 177 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BCDA
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.biocardia.com
Phone650-226-0120
Employees20
Year FoundedN/A

Debt

Debt-to-Equity Ratio0.05
Current Ratio1.99
Quick Ratio1.99

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$710,000.00
Price / Sales70.02
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.35 per share
Price / Book11.43

Profitability

EPS (Most Recent Fiscal Year)($2.61)
Net Income$-14,710,000.00
Net Margins-5,103.95%
Return on Equity-496.87%
Return on Assets-178.90%

Miscellaneous

Outstanding Shares12,429,000
Market Cap$49.72 million
Next Earnings Date4/8/2021 (Estimated)
OptionableNot Optionable
$4.00
-0.09 (-2.20 %)
(As of 01/27/2021 02:34 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BCDA News and Ratings via Email

Sign-up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BioCardia (NASDAQ:BCDA) Frequently Asked Questions

How has BioCardia's stock been impacted by Coronavirus?

BioCardia's stock was trading at $3.59 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BCDA shares have increased by 11.4% and is now trading at $4.00.
View which stocks have been most impacted by COVID-19.

Is BioCardia a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCardia in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BioCardia stock.
View analyst ratings for BioCardia or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than BioCardia?

Wall Street analysts have given BioCardia a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioCardia wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is BioCardia's next earnings date?

BioCardia is scheduled to release its next quarterly earnings announcement on Thursday, April 8th 2021.
View our earnings forecast for BioCardia.

How were BioCardia's earnings last quarter?

BioCardia, Inc. (NASDAQ:BCDA) posted its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.02. The business earned $0.03 million during the quarter, compared to the consensus estimate of $0.11 million. BioCardia had a negative trailing twelve-month return on equity of 496.87% and a negative net margin of 5,103.95%.
View BioCardia's earnings history.

When did BioCardia's stock split? How did BioCardia's stock split work?

Shares of BioCardia reverse split on Friday, November 3rd 2017. The 1-12 reverse split was announced on Thursday, November 2nd 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 2nd 2017. An investor that had 100 shares of BioCardia stock prior to the reverse split would have 8 shares after the split.

What price target have analysts set for BCDA?

2 equities research analysts have issued 12 month price objectives for BioCardia's stock. Their forecasts range from $7.00 to $11.50. On average, they anticipate BioCardia's stock price to reach $9.25 in the next year. This suggests a possible upside of 131.3% from the stock's current price.
View analysts' price targets for BioCardia or view Wall Street analyst' top-rated stocks.

Who are some of BioCardia's key competitors?

Some companies that are related to BioCardia include Gamida Cell (GMDA), Genfit (GNFT), Fennec Pharmaceuticals (FENC), Idera Pharmaceuticals (IDRA), Ayala Pharmaceuticals (AYLA), Pluristem Therapeutics (PSTI), La Jolla Pharmaceutical (LJPC), Outlook Therapeutics (OTLK), Aziyo Biologics (AZYO), Champions Oncology (CSBR), Dyadic International (DYAI), Protalix BioTherapeutics (PLX), BiomX (PHGE), Genocea Biosciences (GNCA) and TRACON Pharmaceuticals (TCON).
View all of BCDA's competitors.

What other stocks do shareholders of BioCardia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCardia investors own include Arotech (ARTX), CytoDyn (CYDY), (SAND), China Gold International Resources Corp. Ltd. (CGG.TO) (CGG), BioSolar (BSRC), Blink Charging (BLNK), Aurcana Silver (AUNFF), (ANIX), American Manganese Inc. (AMY.V) (AMY) and (ALT).

Who are BioCardia's key executives?

BioCardia's management team includes the following people:
  • Dr. Peter A. Altman, CEO, Pres & Director (Age 54, Pay $362.7k)
  • Mr. David McClung, Chief Financial Officer (Age 58, Pay $302.25k)
  • Dr. Eric Henricus J. Duckers, Chief Medical Officer (Age 53, Pay $350k)
  • Mr. Phil Pesta, VP of Operations (Age 55)
  • Dr. Ian McNiece Ph.D., Chief Scientific Officer (Age 67)
  • Mr. Edward M. Gillis, Sr. VP of Devices (Age 59)

When did BioCardia IPO?

(BCDA) raised $51 million in an initial public offering on the week of July 20th 2015. The company issued 3,900,000 shares at $12.00-$14.00 per share. Cantor Fitzgerald & Co. acted as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers.

What is BioCardia's stock symbol?

BioCardia trades on the NASDAQ under the ticker symbol "BCDA."

How do I buy shares of BioCardia?

Shares of BCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioCardia's stock price today?

One share of BCDA stock can currently be purchased for approximately $4.00.

How big of a company is BioCardia?

BioCardia has a market capitalization of $49.72 million and generates $710,000.00 in revenue each year. The company earns $-14,710,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis. BioCardia employs 20 workers across the globe.

What is BioCardia's official website?

The official website for BioCardia is www.biocardia.com.

How can I contact BioCardia?

BioCardia's mailing address is 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA, 94070. The company can be reached via phone at 650-226-0120 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.